Home > Company News > Cyprotex Extends Time Dependent Inhibition Service to Include the Cytochrome P450 Isoform, CYP2B6
Cyprotex Extends Time Dependent Inhibition Service to Include the Cytochrome P450 Isoform, CYP2B6
October 19th 2010
CyprotexPLC (LSE:CRX), the preclinicalADMETox services company, today announces that it has extended its time-dependent inhibition service to include the cytochromeP450 (CYP450) isoform, CYP2B6.
Inhibition of the various CYP450isoforms, including CYP2B6, is one of the main causes of drug-drug interactions. Drug-drug interactions can cause otherwise safe medicines to accumulate in the body resulting in toxicity.
A US FDA update paper by Huanget al., 2008 (JClinPharmacol48; 662-670) has highlighted the importance of CYP2B6 in clinical interactions and recommends that CYP2B6 should be investigated in vitro when assessing whether enzyme inhibition or induction has the potential to produce a drug interaction.
CYP450 inhibition can produce either reversible or irreversible drug-drug interactions. Time-dependent inhibition assays identify compounds which have the potential to form an irreversible drug-drug interaction. These types of drug-drug interactions, although less common, are more serious because the inhibited enzyme must be re-synthesised by the liver before metabolism is restored.
The range of validated CYP450isoforms in Cyprotex’s time-dependent inhibition service now include CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. These isoforms are also available in Cyprotex’sCYP450 reversible inhibition service. Used in combination, these assays act as valuable tools in identifying potential drug-drug interactions, and distinguishing between reversible and irreversible inhibition.
Dr. KatyaTsaioun, Cyprotex’s Chief Scientific Officer, comments on the launch of this new service: “Time-dependent CYP inhibition is a growing concern to the pharmaceutical industry because of the increasing proportion of patients on multiple medications. Due to the serious toxicity implications of irreversible CYP interactions, understanding potential drug-drug interaction liabilities at an early stage in drug discovery is critical. Cyprotex is pleased to provide drug-discovery companies with the most advanced assays for identifying potentials for drug-drug interactions early in the process.”
Dr KatyaTsaioun, Chief Scientific Officer
Dr Anthony Baxter, Chief Executive Officer
Tel: +44 (0) 1625 505 100 firstname.lastname@example.org www.cyprotex.com